PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma

被引：0
|
作者：
Kim, Sue Min
Park, Jung Hee
Nam, Ky-Youb
Han, June H-J
Kim, Kyu-Tae
Yoon, Jeong Hyeok
Sengupta, Sandip
Sim, Taebo
Shin, Sang Joon
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
411
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Anti-Tumor Effect of Pan-RAF Inhibitor in NSCLC Cells Harboring BRAF Mutation
    Miyauchi, S.
    Shien, K.
    Araki, K.
    Nakata, K.
    Miura, A.
    Namba, K.
    Suzawa, K.
    Yamamoto, H.
    Okazaki, M.
    Tomida, S.
    Toyooka, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S423 - S424
  • [12] Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma
    Girotti, Maria R.
    Pedersen, Malin
    Sanchez-Laorden, Berta
    Viros, Amaya
    Turajlic, Samra
    Niculescu-Duvaz, Dan
    Zambon, Alfonso
    Sinclair, John
    Hayes, Andrew
    Gore, Martin
    Springer, Caroline
    Larkin, James
    Jorgensen, Claus
    Marais, Richard
    CANCER RESEARCH, 2013, 73 (08)
  • [13] Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
    Girotti, Maria R.
    Pedersen, Malin
    Sanchez-Laorden, Berta
    Viros, Amaya
    Turajlic, Samra
    Niculescu-Duvaz, Dan
    Zambon, Alfonso
    Sinclair, John
    Hayes, Andrew
    Gore, Martin
    Lorigan, Paul
    Springer, Caroline
    Larkin, James
    Jorgensen, Claus
    Marais, Richard
    CANCER DISCOVERY, 2013, 3 (02) : 158 - 167
  • [14] Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma
    Takano, Kohei
    Munehira, Yoichi
    Hatanaka, Mana
    Murakami, Ryo
    Shibata, Yoshihiro
    Shida, Takeshi
    Takeuchi, Kosuke
    Takechi, Sho
    Tabata, Toshiki
    Shimada, Takashi
    Kishikawa, Shuhei
    Matsui, Yumi
    Ubukata, Osamu
    Seki, Takahiko
    Kaneta, Yasuyuki
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (03) : 317 - 332
  • [15] BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
    Vido, Michael J.
    Le, Kaitlyn
    Hartsough, Edward J.
    Aplin, Andrew E.
    CELL REPORTS, 2018, 25 (06): : 1501 - +
  • [16] The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
    Phadke, Manali S.
    Sini, Patrizia
    Smalley, Keiran S. M.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (06) : 1354 - 1364
  • [17] Discovery of TAK-632: A selective kinase inhibitor of pan-RAF with potent antitumor activity against BRAF and NRAS mutant melanomas
    Okaniwa, Masanori
    Hirose, Masaaki
    Arita, Takeo
    Yabuki, Masato
    Nakamura, Akita
    Takagi, Terufumi
    Kawamoto, Tomohiro
    Uchiyama, Noriko
    Sumita, Akihiko
    Tsutsumi, Shunichirou
    Tottori, Tsuneaki
    Inui, Yoshitaka
    Sang, Bi-Ching
    Yano, Jason
    Aertgeerts, Kathleen
    Yoshida, Sei
    Ishikawa, Tomoyasu
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [18] A selective and potent pan-RAF inhibitor, HM95573 exhibits high therapeutic potential as a next-generation RAF inhibitor by direct inhibition of RAF kinase activity in BRAF or RAS mutant cancers
    Namgoong, G.
    Kim, S. H.
    Song, T. H.
    Bae, I. H.
    Ahn, Y. G.
    Lee, J. H.
    Choi, K.
    Lee, K. H.
    Kim, Y. H.
    Lee, Y. M.
    Suh, K. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S127 - S127
  • [19] Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.
    Kim, Tae Won
    Lee, Jeeyun
    Shin, Sang Joon
    Kim, Jin-Soo
    Kim, Yu Jung
    Han, Hye Sook
    Lee, Soo Jung
    Lim, Hyeong-Seok
    Hong, Yoon-hee
    Noh, Young Su
    Kyoung, Yujung
    Han, Oakpil
    Yoon, Jiyeon
    Lim, Jeong Ah
    Kim, Suk Ran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [20] NOVEL PAN-RAF INHIBITOR BELVARAFENIB AS A PROMISING TARGETED THERAPY FOR BRAF-ALTERED PEDIATRIC LOW-GRADE GLIOMAS.
    Gonzalez, Maxine
    Lebert, Brittany
    Campion, Stephani
    Aguilar-Bonilla, Ana
    Smith, Amy
    NEURO-ONCOLOGY, 2023, 25
12345